RemedyRepack Recalls Glipizide Tablets for Failed Dissolution Specifications
RemedyRepack Inc. is recalling Glipizide 2.5 mg ER tablets because they failed to meet dissolution specifications. The product was distributed to a customer in Florida.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' rating under the rubric, particularly given the potential for significant health consequences if the medication does not dissolve properly.
Plain-English summary
RemedyRepack Inc. is recalling Glipizide 2.5 mg ER Tablets, NDC 52125-0764-02, due to failed dissolution specifications. The tablets were manufactured by Watson Laboratories, Inc., and repackaged by RemedyRepack Inc. The specific lot involved is B0129373-021916, with an expiration date of 10/17.
The recall is classified as FDA Class II. The product was distributed to a sold customer in Florida. The quantity involved is 630 pills, packaged as 21 bottles containing 30 pills each.
Consumers who have this product should stop using it and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The recall is being conducted to ensure the medication meets required quality standards for dissolution.
The recalled product
- Product
- Glipizide 2.5 mg ER Tablets, Manufactured by Watson Laboratories, Inc., Parsippany, NJ 07054, Repackaged by RemedyRepack, Indiana, PA 15701, NDC 52125-0764-02
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # B0129373-021916
- Exp. 10/17 00591-0900-30 Original NDC 52125-0764-02 RemedyRepack NDC
Distribution
Distributed in 1 state:
Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22